WASHINGTON, Aug 17 (Reuters) - DuPont Pharmaceuticals Co. said
Thursday it had stopped circulating certain advertisements for
its anti-HIV drug Sustiva that U.S. regulators charged were
The Food and Drug Administration took issue with ads geared
toward consumers and physicians containing the slogan "So Life
The phrase is misleading because it implies that Sustiva
improves survival for patients with HIV, the virus that causes
AIDS, the FDA said in a letter dated July 18.
"However, Sustiva's impact on improving survival in patients
with HIV has not been demonstrated by substantial evidence,"
the FDA wrote.
The letter also said claims regarding dosing instructions and
side effects were misleading.
A spokesman for DuPont Pharmaceuticals, a subsidiary of
chemical giant DuPont Co., said the company was no longer
distributing the ads, which he said ran mostly in magazines and
other publications marketed to people infected with HIV.
"We have corrected those points that the FDA made," spokesman
Thomas Barry said.
The FDA routinely monitors drug companies' promotion of their
products. The agency this year has sent dozens of notices to
companies charging violations of requirements to make
advertisements accurate and balanced. The letter to DuPont was
posted on the FDA Web site Thursday.
Sustiva is one of DuPont's top-selling drug products. The
drug's worldwide sales for the first six months of 2000 were